Cargando…
Long term follow-up report of cardiac toxicity in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation
BACKGROUND: Tandem autologous hematopoietic stem cell transplantation (ta-HSCT) is a standard treatment for multiple myeloma (MM). Patients receive a high-dose cyclophosphamide (CY), followed by two myeloablative cycles of melphalan (MEL). There are scarce data about long term cardiotoxicity. PATIEN...
Autores principales: | Kozelj, Mirta, Zver, Samo, Zadnik, Vesna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Versita, Warsaw
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691086/ https://www.ncbi.nlm.nih.gov/pubmed/23801913 http://dx.doi.org/10.2478/raon-2013-0019 |
Ejemplares similares
-
Echocardiographic Assessment of Left Ventricular Function in Type 1 Gaucher's Disease
por: Koželj, Mirta, et al.
Publicado: (2010) -
Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma
por: Maffini, Enrico, et al.
Publicado: (2019) -
Tandem Autologous Hematopoietic Stem Cell Transplantation in Very Young Patients with Multiple Myeloma
por: Naithani, Rahul, et al.
Publicado: (2020) -
Impact of tandem autologous stem cell transplantation and response to transplant in the outcome of multiple myeloma
por: Bergantim, Rui, et al.
Publicado: (2012) -
Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation
por: Uy, Geoffrey L., et al.
Publicado: (2015)